Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardlytics, Inc.CDLX · Entity 7603 | Director | May 23, 2023 | May 25, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardlytics, Inc.
Report date May 23, 2023 · Filed May 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,263 |
Reported balance
After 2023-05-24 transaction · row 1
1 source rowRow 1 · 2023-05-24 · Exercise / conversion · Acquired 6,465 · Balance 68,263 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 28,547 |
Reported balance
After 2023-05-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-23 · Grant · Acquired 28,547 · Balance 28,547 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F2: The RSUs shall vest in full on the one-year anniversary of the date of grant, provided that the Reporting Person remains a director of the Issuer on such vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-24 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-05-24 · Exercise / conversion · Disposed 6,465 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F3: The RSUs vested in full on the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent.
F2: The RSUs shall vest in full on the one-year anniversary of the date of grant, provided that the Reporting Person remains a director of the Issuer on such vesting date.
F3: The RSUs vested in full on the one-year anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 24, 2023 Filed May 25, 2023 17:01 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionRestricted Stock Units · Derivative | 6,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032213 · doc4.xml · derivative · entry 3 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,465 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F3 · derivative.exercise_date: The RSUs vested in full on the one-year anniversary of the date of grant. F3 · derivative.expiration_date: The RSUs vested in full on the one-year anniversary of the date of grant. Read SEC document |
| May 24, 2023 Filed May 25, 2023 17:01 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 6,465 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-032213 · doc4.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. Read SEC document |
| May 23, 2023 Filed May 25, 2023 17:01 UTC | Cardlytics, Inc. CDLX · Entity 7603 | GrantRestricted Stock Units · Derivative | 28,547 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032213 · doc4.xml · derivative · entry 2 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,547 Underlying: Common Stock · 28,547 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F2 · derivative.exercise_date: The RSUs shall vest in full on the one-year anniversary of the date of grant, provided that the Reporting Person remains a director of the Issuer on such vesting date. F2 · derivative.expiration_date: The RSUs shall vest in full on the one-year anniversary of the date of grant, provided that the Reporting Person remains a director of the Issuer on such vesting date. Read SEC document |
| November 09, 2022 Filed Nov 9, 2022 16:49 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 3,000 | $3.80 | $11,398.50 |
DisclosureSEC source: 0001666071-22-000144 · wf-form4_166803053753323.xml · nonDerivative · entry 3 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,798 Read SEC document |
| November 08, 2022 Filed Nov 9, 2022 16:49 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 6,000 | $3.95 | $23,698.20 |
DisclosureSEC source: 0001666071-22-000144 · wf-form4_166803053753323.xml · nonDerivative · entry 2 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,798 Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 16:49 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 6,000 | $4.24 | $25,450.80 |
DisclosureSEC source: 0001666071-22-000144 · wf-form4_166803053753323.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,798 Read SEC document |
| August 15, 2022 Filed Aug 15, 2022 17:40 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 2,000 | $16.92 | $33,842.00 |
DisclosureSEC source: 0001666071-22-000113 · wf-form4_166059709850353.xml · nonDerivative · entry 4 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,798 Read SEC document |
| August 12, 2022 Filed Aug 15, 2022 17:40 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 1 | $16.65 | $16.65 |
DisclosureSEC source: 0001666071-22-000113 · wf-form4_166059709850353.xml · nonDerivative · entry 3 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,798 Read SEC document |
| August 12, 2022 Filed Aug 15, 2022 17:40 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 1,999 | $16.66 | $33,303.14 |
DisclosureSEC source: 0001666071-22-000113 · wf-form4_166059709850353.xml · nonDerivative · entry 2 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,797 Read SEC document |
| August 12, 2022 Filed Aug 15, 2022 17:40 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 1,000 | $16.79 | $16,792.90 |
DisclosureSEC source: 0001666071-22-000113 · wf-form4_166059709850353.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,798 Read SEC document |
| May 27, 2022 Filed May 31, 2022 17:21 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 1,000 | $27.39 | $27,391.10 |
DisclosureSEC source: 0001666071-22-000078 · wf-form4_165403203192498.xml · nonDerivative · entry 4 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,798 Read SEC document |
| May 27, 2022 Filed May 31, 2022 17:21 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 1,000 | $27.18 | $27,175.00 |
DisclosureSEC source: 0001666071-22-000078 · wf-form4_165403203192498.xml · nonDerivative · entry 3 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,798 Read SEC document |
| May 27, 2022 Filed May 31, 2022 17:21 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 1,000 | $27.31 | $27,309.70 |
DisclosureSEC source: 0001666071-22-000078 · wf-form4_165403203192498.xml · nonDerivative · entry 2 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,798 Read SEC document |
| May 27, 2022 Filed May 31, 2022 17:21 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 2,000 | $27.56 | $55,119.80 |
DisclosureSEC source: 0001666071-22-000078 · wf-form4_165403203192498.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,798 Read SEC document |
| May 24, 2022 Filed May 24, 2022 20:50 UTC | Cardlytics, Inc. CDLX · Entity 7603 | GrantRestricted Stock Units · Derivative | 6,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-22-000070 · wf-form4_165343983025707.xml · derivative · entry 3 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,465 Underlying: Common Stock · 6,465 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F3 · derivative.exercise_date: The RSUs shall vest in full on the one-year anniversary of the date of grant, provided that the Reporting Person remains a director of the Issuer on such vesting date. F3 · derivative.expiration_date: The RSUs shall vest in full on the one-year anniversary of the date of grant, provided that the Reporting Person remains a director of the Issuer on such vesting date. Read SEC document |
| May 21, 2022 Filed May 24, 2022 20:50 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionRestricted Stock Units · Derivative | 1,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-22-000070 · wf-form4_165343983025707.xml · derivative · entry 2 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,701 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F2 · derivative.exercise_date: The RSUs vested in full on the one-year anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs vested in full on the one-year anniversary of the date of grant. Read SEC document |
| May 21, 2022 Filed May 24, 2022 20:50 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 1,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-22-000070 · wf-form4_165343983025707.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. Read SEC document |
| May 10, 2022 Filed May 10, 2022 16:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 1,000 | $29.52 | $29,520.50 |
DisclosureSEC source: 0001666071-22-000064 · wf-form4_165221445632563.xml · nonDerivative · entry 6 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,097 Read SEC document |
| May 10, 2022 Filed May 10, 2022 16:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 100 | $29.48 | $2,947.99 |
DisclosureSEC source: 0001666071-22-000064 · wf-form4_165221445632563.xml · nonDerivative · entry 5 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,097 Read SEC document |
| May 10, 2022 Filed May 10, 2022 16:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 900 | $29.70 | $26,730.00 |
DisclosureSEC source: 0001666071-22-000064 · wf-form4_165221445632563.xml · nonDerivative · entry 4 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,997 Read SEC document |
| May 09, 2022 Filed May 10, 2022 16:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 300 | $28.35 | $8,504.40 |
DisclosureSEC source: 0001666071-22-000064 · wf-form4_165221445632563.xml · nonDerivative · entry 3 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,097 Read SEC document |
| May 09, 2022 Filed May 10, 2022 16:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 100 | $28.34 | $2,834.00 |
DisclosureSEC source: 0001666071-22-000064 · wf-form4_165221445632563.xml · nonDerivative · entry 2 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,797 Read SEC document |
| May 09, 2022 Filed May 10, 2022 16:28 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 600 | $28.35 | $17,010.00 |
DisclosureSEC source: 0001666071-22-000064 · wf-form4_165221445632563.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,697 Read SEC document |
| August 30, 2021 Filed Aug 31, 2021 17:44 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 1,000 | $89.85 | $89,850.00 |
DisclosureSEC source: 0001666071-21-000169 · wf-form4_163044625575972.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,097 Read SEC document |
| August 20, 2021 Filed Aug 23, 2021 16:32 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 1,000 | $81.41 | $81,409.90 |
DisclosureSEC source: 0001666071-21-000165 · wf-form4_162975074377230.xml · nonDerivative · entry 2 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,097 Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 16:32 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 1,000 | $78.61 | $78,606.80 |
DisclosureSEC source: 0001666071-21-000165 · wf-form4_162975074377230.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,097 Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 20:38 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionRestricted Stock Units · Derivative | 2,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-21-000123 · wf-form4_162276705776124.xml · derivative · entry 2 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,023 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F2 · derivative.exercise_date: The RSUs vested in full on the one-year anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs vested in full on the one-year anniversary of the date of grant. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 20:38 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 2,023 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001666071-21-000123 · wf-form4_162276705776124.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. Read SEC document |
| May 25, 2021 Filed Jun 1, 2021 17:03 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 1,000 | $103.11 | $103,110.00 |
DisclosureSEC source: 0001666071-21-000115 · wf-form4_162258140244754.xml · nonDerivative · entry 3 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,074 F3 · price: The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $102.68 to $103.43, inclusive. Read SEC document |
| May 21, 2021 Filed Jun 1, 2021 17:03 UTC | Cardlytics, Inc. CDLX · Entity 7603 | GrantRestricted Stock Units · Derivative | 1,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-21-000115 · wf-form4_162258140244754.xml · derivative · entry 4 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,701 Underlying: Common Stock · 1,701 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F5 · derivative.exercise_date: The RSUs shall vest in full on the one-year anniversary of the date of grant, provided that the Reporting Person remains a director of the Issuer on such vesting date. F5 · derivative.expiration_date: The RSUs shall vest in full on the one-year anniversary of the date of grant, provided that the Reporting Person remains a director of the Issuer on such vesting date. Read SEC document |
| May 14, 2021 Filed Jun 1, 2021 17:03 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 1,000 | $92.92 | $92,920.00 |
DisclosureSEC source: 0001666071-21-000115 · wf-form4_162258140244754.xml · nonDerivative · entry 2 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,074 F2 · price: The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $92.8863 to $92.98, inclusive. Read SEC document |
| May 14, 2021 Filed Jun 1, 2021 17:03 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 1,000 | $91.57 | $91,570.00 |
DisclosureSEC source: 0001666071-21-000115 · wf-form4_162258140244754.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,074 F1 · price: The price reported is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $91.565 to $91.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 16:54 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionRestricted Stock Units · Derivative | 6,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-20-000198 · wf-form4_159320487037454.xml · derivative · entry 2 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F2 · derivative.exercise_date: The RSUs vested in full on the one-year anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs vested in full on the one-year anniversary of the date of grant. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 16:54 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 6,353 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001666071-20-000198 · wf-form4_159320487037454.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 18:25 UTC | Cardlytics, Inc. CDLX · Entity 7603 | GrantRestricted Stock Units · Derivative | 2,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001666071-20-000177 · wf-form4_159130951041035.xml · derivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,023 Underlying: Common Stock · 2,023 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F2 · derivative.exercise_date: The RSUs shall vest in full on the one-year anniversary of the date of grant, provided that the Reporting Person remains a director of the Issuer on such vesting date. F2 · derivative.expiration_date: The RSUs shall vest in full on the one-year anniversary of the date of grant, provided that the Reporting Person remains a director of the Issuer on such vesting date. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 21:51 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 100 | $44.81 | $4,481.00 |
DisclosureSEC source: 0001666071-20-000083 · wf-form4_158440986843312.xml · nonDerivative · entry 6 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,721 Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 21:51 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 400 | $44.87 | $17,948.00 |
DisclosureSEC source: 0001666071-20-000083 · wf-form4_158440986843312.xml · nonDerivative · entry 5 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,621 Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 21:51 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 500 | $44.45 | $22,225.05 |
DisclosureSEC source: 0001666071-20-000083 · wf-form4_158440986843312.xml · nonDerivative · entry 4 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,221 Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:51 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 401 | $44.99 | $18,040.99 |
DisclosureSEC source: 0001666071-20-000083 · wf-form4_158440986843312.xml · nonDerivative · entry 3 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,721 Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:51 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 299 | $45.00 | $13,455.00 |
DisclosureSEC source: 0001666071-20-000083 · wf-form4_158440986843312.xml · nonDerivative · entry 2 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,320 Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:51 UTC | Cardlytics, Inc. CDLX · Entity 7603 | PurchaseCommon Stock | 300 | $45.01 | $13,503.00 |
DisclosureSEC source: 0001666071-20-000083 · wf-form4_158440986843312.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,021 Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 16:32 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 100,898 | $32.00 | $3,228,594.74 |
DisclosureSEC source: 0001209191-19-045917 · doc4.xml · nonDerivative · entry 3 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.75 - $32.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reportable securities are held directly by Canaan VIII, LP (the "Canaan Fund"). Canaan Partners VIII LLC ("Canaan VIII" and together with the Canaan Fund, the "Canaan Entities") is the sole general partner of the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan VIII, collectively. John Balen, a manager and member of Canaan VIII, serves as the representative of the Canaan Entities on the Issuer's board of directors. Mr. Balen disclaims beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest, if any, in such securities by virtue of the limited liability company interests he owns in Canaan VIII. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 16:32 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 2,600 | $33.11 | $86,073.00 |
DisclosureSEC source: 0001209191-19-045917 · doc4.xml · nonDerivative · entry 2 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 100,898 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 - $33.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reportable securities are held directly by Canaan VIII, LP (the "Canaan Fund"). Canaan Partners VIII LLC ("Canaan VIII" and together with the Canaan Fund, the "Canaan Entities") is the sole general partner of the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan VIII, collectively. John Balen, a manager and member of Canaan VIII, serves as the representative of the Canaan Entities on the Issuer's board of directors. Mr. Balen disclaims beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest, if any, in such securities by virtue of the limited liability company interests he owns in Canaan VIII. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 16:32 UTC | Cardlytics, Inc. CDLX · Entity 7603 | SaleCommon Stock | 84,185 | $31.80 | $2,676,965.14 |
DisclosureSEC source: 0001209191-19-045917 · doc4.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 103,498 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.75 - $32.185, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: The reportable securities are held directly by Canaan VIII, LP (the "Canaan Fund"). Canaan Partners VIII LLC ("Canaan VIII" and together with the Canaan Fund, the "Canaan Entities") is the sole general partner of the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan VIII, collectively. John Balen, a manager and member of Canaan VIII, serves as the representative of the Canaan Entities on the Issuer's board of directors. Mr. Balen disclaims beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest, if any, in such securities by virtue of the limited liability company interests he owns in Canaan VIII. Read SEC document |
| June 25, 2019 Filed Jun 26, 2019 17:31 UTC | Cardlytics, Inc. CDLX · Entity 7603 | GrantRestricted Stock Units · Derivative | 6,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039146 · doc4.xml · derivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,353 Underlying: Common Stock · 6,353 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F2 · derivative.exercise_date: The RSUs shall vest in full on the one-year anniversary of the date of grant, provided that the Reporting Person remains a director of the Issuer on such vesting date. F2 · derivative.expiration_date: The RSUs shall vest in full on the one-year anniversary of the date of grant, provided that the Reporting Person remains a director of the Issuer on such vesting date. Read SEC document |
| March 09, 2019 Filed Apr 10, 2019 17:34 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionRestricted Stock Units · Derivative | 8,484 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-024294 · doc4.xml · derivative · entry 3 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,484 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F4 · derivative.exercise_date: The RSUs vested in full on the one-year anniversary of the date of grant. F4 · derivative.expiration_date: The RSUs vested in full on the one-year anniversary of the date of grant. Read SEC document |
| March 09, 2019 Filed Apr 10, 2019 17:34 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 8,484 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-024294 · doc4.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent. F2 · balance_after: Includes 2,771 shares received by the Reporting Person pursuant to pro rata distributions, for no consideration, by Canaan VIII, LP (the "Canaan Fund") on September 17, 2018, January 29, 2019 and April 9, 2019. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 09, 2018 Filed Aug 9, 2018 21:36 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionWarrant (Right to Buy) · Derivative | 122,777 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-046120 · doc4.xml · derivative · entry 3 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 122,777 shares Expires 2023-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares acquired upon exercise of the warrant were acquired through a net exercise procedure in accordance with the terms of the warrant and did not involve any sale of shares. F2 · ownership.nature: The reportable securities are held directly by Canaan VIII L.P. (the "Canaan Fund"). Canaan Partners VIII LLC ("Canaan VIII" and together with the Canaan Fund, the "Canaan Entities") is the sole general partner of the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan VIII, collectively. John Balen, a manager and member of Canaan VIII, serves as the representative of the Canaan Entities on the Issuer's board of directors. Mr. Balen disclaims beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest, if any, in such securities by virtue of the limited liability company interests he owns in Canaan VIII. Read SEC document |
| August 09, 2018 Filed Aug 9, 2018 21:36 UTC | Cardlytics, Inc. CDLX · Entity 7603 | Exercise / conversionCommon Stock | 122,777 | $0.00 | $49.11 |
DisclosureSEC source: 0001209191-18-046120 · doc4.xml · nonDerivative · entry 1 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,368,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares acquired upon exercise of the warrant were acquired through a net exercise procedure in accordance with the terms of the warrant and did not involve any sale of shares. F2 · ownership.nature: The reportable securities are held directly by Canaan VIII L.P. (the "Canaan Fund"). Canaan Partners VIII LLC ("Canaan VIII" and together with the Canaan Fund, the "Canaan Entities") is the sole general partner of the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan VIII, collectively. John Balen, a manager and member of Canaan VIII, serves as the representative of the Canaan Entities on the Issuer's board of directors. Mr. Balen disclaims beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest, if any, in such securities by virtue of the limited liability company interests he owns in Canaan VIII. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 21:36 UTC | Cardlytics, Inc. CDLX · Entity 7603 | GrantWarrant (Right to Buy) · Derivative | 122,777 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-046120 · doc4.xml · derivative · entry 2 BALEN JOHN V · CIK 0001181211 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 122,777 Underlying: Common Stock · 122,777 shares Expires 2023-08-07 F3 · kind: The warrants were acquired pursuant to an agreement between the Reporting Person and the Issuer, dated May 4, 2017. The acquisition was approved by the Issuer's Board of Directors on May 4, 2017 and constitutes an exempt acquisition under Rule 16b-3(d)(1) of the Securities Exchange Act of 1934, as amended. The number of shares to be acquired (if any) upon exercise of the warrants could only be determined 180 days following the date of the Issuer's final prospectus, dated February 8, 2018, relating to its initial public offering. F2 · ownership.nature: The reportable securities are held directly by Canaan VIII L.P. (the "Canaan Fund"). Canaan Partners VIII LLC ("Canaan VIII" and together with the Canaan Fund, the "Canaan Entities") is the sole general partner of the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan VIII, collectively. John Balen, a manager and member of Canaan VIII, serves as the representative of the Canaan Entities on the Issuer's board of directors. Mr. Balen disclaims beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest, if any, in such securities by virtue of the limited liability company interests he owns in Canaan VIII. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.